FORMULATION ARTICLES
-
Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic Disease
Suppressor tRNAs could unlock a scalable new way to treat genetic diseases caused by nonsense mutations, restoring full-length proteins across multiple indications.
-
Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset
In this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.
-
Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics
Designing repeat-dose RNA means engineering around immune recognition — optimizing payloads, purity, and delivery early to sustain efficacy, tolerability, and durability across multiple administrations.
-
A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis
Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.
-
A New Approach To RNA Synthesis And Purification: Rethinking A Persistent Bottleneck
Photocleavable supports enable light-triggered RNA release, reducing reliance on chromatography and streamlining synthesis, scalability, and purity for complex RNA therapeutics.
-
Oligos, mRNA, Or Gene Editing: Where Should You Bet?
Investing in RNA and gene editing requires balancing risk, timing, and scale — understanding how oligos, mRNA, and CRISPR each drive value across a converging biotech landscape.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Lipid nanoparticles enable efficient gene editing in hard-to-transfect cells like T-cells and blood stem cells, which offers scalable, clinically relevant methods for developing advanced therapies for cancer and rare diseases.
-
Explore results from a study screening novel LNP formulations for physicochemical attributes, in vitro potency, and in vivo immunogenicity in both SARS-CoV-2 and influenza vaccine applications.
-
Advancements in purification, delivery mechanisms, and stability during storage and transport will enable the future of mRNA-based therapies.
-
Understand how Microfluidic Modulation Spectroscopy (MMS) provides early insights into RNA degradation within LNP formulations, offering a label-free approach to monitoring chemical integrity.
-
By following some of the best practices in freezing mRNA, you can effectively balance product quality, cost-effectiveness, process safety, and efficiency.
-
Lipid nanoparticles enable precise, non-viral gene editing in T cells to achieve high HDR efficiency and viability in scalable workflows. Explore how this approach overcomes viral vector limitations.
-
Explore results generated from an internal study using a proprietary mRNA-LNP formulation and UHPLC-CAD, a powerful technique for the analysis of compounds that do not contain chromophores.